Lymphatic changes in cancer and drug delivery to the lymphatics in solid tumors

Cote, Brianna; Rao, Deepa; Alany, Raid G.; Kwon, Glen S.; Alani, Adam W.G.

doi:10.1016/j.addr.2019.08.009

Cited by 38 publications

(37 citation statements)

References 179 publications

(335 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Meanwhile, with the increase of the particle size of PLGA NPs, their brain accumulation efficiency gradually decreased, which was only 6.0% for 131 nm PLGA NPs and 3.8% for 181 nm PLGA NPs (P. Zhao et al, 2020). These results corroborate with previous reports that the transport of NPs to lymph node was strictly limited by the size‐restriction of the lymph node reticular network (Cote et al, 2019; Mei et al, 2018) and the size of NPs (L. X. Zhang et al, 2018). Therefore, the appropriate physical properties (such as particle size) should be taken into consideration for improved brain accumulation efficiency under the SC‐route.…”

Section: Ad Targeted Delivery Of Nanomedicinessupporting

confidence: 92%

Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases

Zhang

Sun

Chen

et al. 2021

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a progressive neurodegenerative disease that affects populations around the world. Many therapeutics have been investigated for AD diagnosis and/or therapy, but the efficacy is largely limited by the poor bioavailability of drugs and by the presence of the blood–brain barrier. Recently, the development of nanomedicines enables efficient drug delivery to the brain, but the complex pathological mechanism of AD prevents them from successful treatment. As a type of advanced nanomedicine, multifunctional nanoassemblies self‐assembled from nanoscale imaging or therapeutic agents can simultaneously target multiple pathological factors, showing great potential in the diagnosis and therapy of AD. To help readers better understand this emerging field, in this review, we first introduce the pathological mechanisms and the potential drug candidates of AD, as well as the design strategies of nanoassemblies for improving AD targeting efficiency. Moreover, the progress of dynamic nanoassemblies that can diagnose and/or treat AD in response to the endogenous or exogenous stimuli will be described. Finally, we conclude with our perspectives on the future development in this field. The objective of this review is to outline the latest progress of using nanoassemblies to overcome the complex pathological environment of AD for improved diagnosis and therapy, in hopes of accelerating the future development of intelligent AD nanomedicines. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease Diagnostic Tools > in vivo Nanodiagnostics and Imaging

show abstract

Section: Ad Targeted Delivery Of Nanomedicinessupporting

confidence: 92%

Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases

Zhang

Sun

Chen

et al. 2021

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…That study’s findings are further strong evidence that the lymphatic system is a major pathway for cancer metastasis. These findings also suggest that studies on lymphatic targeting and migration of anticancer drugs are crucial, and, in fact, researchers have studied a number of targeting strategies and benefits based on the structural and physiological characteristics of the lymphatic system related to drug delivery [ 6 , 7 , 8 , 9 ]. Researchers have also reported on improving bioavailability and efficacy through formulations of conventional drugs [ 10 , 11 , 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Enhanced Lymphatic Delivery of Methotrexate Using W/O/W Nanoemulsion: In Vitro Characterization and Pharmacokinetic Study

2020

View full text Add to dashboard Cite

Methotrexate, which is widely used in the treatment of cancer and immune-related diseases, has limitations in use because of its low bioavailability, short half-life, and tissue toxicity. Thus, in this study, a nano-sized water-in-oil-in-water (W/O/W) double emulsion containing methotrexate was prepared to enhance its lymphatic delivery and bioavailability. Based on the results from solubility testing and a pseudo-ternary diagram study, olive oil as the oil, Labrasol as a surfactant, and ethanol as a co-surfactant, were selected as the optimal components for the nanoemulsion. The prepared nanoemulsion was evaluated for size, zeta potential, encapsulation efficiency, pH, morphology, and in vitro release profiles. Furthermore, pharmacokinetics and lymphatic targeting efficiency were assessed after oral and intravenous administration of methotrexate-loaded nanoemulsion to rats. Mean droplet size, zeta potential, encapsulation efficiency, and pH of formulated nanoemulsion were 173.77 ± 5.76 nm, −35.63 ± 0.78 mV, 90.37 ± 0.96%, and 4.07 ± 0.03, respectively. In vitro release profile of the formulation indicated a higher dissolution and faster rate of methotrexate than that of free drug. The prepared nanoemulsion showed significant increases in maximum plasma concentration, area under the plasma concentration-time curve, half-life, oral bioavailability, and lymphatic targeting efficiency in both oral and intravenous administration. Therefore, our research proposes a methotrexate-loaded nanoemulsion as a good candidate for enhancing targeted lymphatic delivery of methotrexate.

show abstract

“…Additionally, it has been reported that intradermal injection can lead to a localized increase in interstitial pressure within the dermis, potentially increasing the rate of ICG drainage and interfering with measurements [26,27]. A proposed solution to this issue has been the delivery of ICG using microneedles (MNs) [28].…”

Section: Introductionmentioning

confidence: 99%

Rational design of a fluorescent microneedle tattoo for minimally invasive monitoring of lymphatic function

Babity

Połomska

Couture³

et al. 2020

Journal of Controlled Release

View full text Add to dashboard Cite

The monitoring of lymphatic drainage is of great importance, particularly in the context of the early detection and diagnosis of several diseases. Existing methods of imaging and monitoring lymphatic drainage can be costly and require trained personnel, posing problems for at-home or point-of-care monitoring. Recently, an alternative approach has been proposed, consisting of using microneedles to deliver a near-infrared (NIR) fluorescent tattoo to the skin, which can be monitored with traditional laboratory-based fluorescence detectors. In this work, we present further development of this approach, using a specifically designed NIR-fluorescent probe and rational optimization of microneedle properties and the spatial location of the NIR dye within the microneedles. Moreover, we demonstrate that this method is compatible with a custom-made portable fluorescence measurement device and able to discriminate between drainage and lack of drainage in vivo in rats.

show abstract

Lymphatic changes in cancer and drug delivery to the lymphatics in solid tumors

Cited by 38 publications

References 179 publications

Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases

Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases

Enhanced Lymphatic Delivery of Methotrexate Using W/O/W Nanoemulsion: In Vitro Characterization and Pharmacokinetic Study

Rational design of a fluorescent microneedle tattoo for minimally invasive monitoring of lymphatic function

Contact Info

Product

Resources

About